Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDr lal pathlabs

    Dr Lal Pathlabs

    Jump to
    • Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y

      Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y

    • Dr Lal PathLab Consolidated September 2025 Net Sales at Rs 730.60 crore, up 10.66% Y-o-Y

      Dr Lal PathLab Consolidated September 2025 Net Sales at Rs 730.60 crore, up 10.66% Y-o-Y

    • Dr Lal PathLab Consolidated June 2025 Net Sales at Rs 669.80 crore, up 11.28% Y-o-Y

      Dr Lal PathLab Consolidated June 2025 Net Sales at Rs 669.80 crore, up 11.28% Y-o-Y

    • Dr Lal PathLab Standalone June 2025 Net Sales at Rs 640.70 crore, up 19.87% Y-o-Y

      Dr Lal PathLab Standalone June 2025 Net Sales at Rs 640.70 crore, up 19.87% Y-o-Y

    • Buy Dr Lal Pathlabs; target of Rs 3100: Emkay

      Buy Dr Lal Pathlabs; target of Rs 3100: Emkay

      Emkay is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 3100 in its research report dated July 20, 2025.

    • Dr Lal PathLabs, Metropolis, others fall up to 2% as Amazon launches home diagnostics services

      Dr Lal PathLabs, Metropolis, others fall up to 2% as Amazon launches home diagnostics services

      Amazon India on Sunday announced the launch of Amazon Diagnostics, an at-home service for customers to book lab tests, schedule and track appointments, and access digital reports through the Amazon app

    • Hold Dr Lal Pathlabs: target of Rs 2,900: ICICI Securities

      Hold Dr Lal Pathlabs: target of Rs 2,900: ICICI Securities

      ICICI Securities recommended hold rating on Dr Lal Pathlabs with a target price of Rs 2,900 in its research report dated April 26, 2025.

    • Buy Dr Lal Pathlabs; target of Rs 3100: Emkay Global Financial

      Buy Dr Lal Pathlabs; target of Rs 3100: Emkay Global Financial

      Emkay Global Financial recommended buy rating on Dr Lal Pathlabs with a target price of Rs 3100 in its research report dated April 26, 2025.

    • Dr Lal PathLabs’ shares slip over 4% as margins likely to see pressure on expansion plans

      Dr Lal PathLabs’ shares slip over 4% as margins likely to see pressure on expansion plans

      Dr Lal PathLabs will prioritize volume expansion as a key growth driver and may avoid implementing price hikes in the near term.

    • Dr Lal PathLab Standalone March 2025 Net Sales at Rs 577.20 crore, up 20.5% Y-o-Y

      Dr Lal PathLab Standalone March 2025 Net Sales at Rs 577.20 crore, up 20.5% Y-o-Y

    • Dr Lal PathLab Consolidated March 2025 Net Sales at Rs 602.60 crore, up 10.49% Y-o-Y

      Dr Lal PathLab Consolidated March 2025 Net Sales at Rs 602.60 crore, up 10.49% Y-o-Y

    • Dr Lal PathLab Consolidated December 2024 Net Sales at Rs 596.70 crore, up 10.73% Y-o-Y

      Dr Lal PathLab Consolidated December 2024 Net Sales at Rs 596.70 crore, up 10.73% Y-o-Y

    • Buy Dr Lal Pathlabs; target of Rs 3250: Emkay Global Financial

      Buy Dr Lal Pathlabs; target of Rs 3250: Emkay Global Financial

      Emkay Global Financial is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 3250 in its research report dated January 30, 2025.

    • Dr Lal PathLab Standalone December 2024 Net Sales at Rs 528.10 crore, up 10.95% Y-o-Y

      Dr Lal PathLab Standalone December 2024 Net Sales at Rs 528.10 crore, up 10.95% Y-o-Y

    • Dr Lal PathLab Standalone September 2024 Net Sales at Rs 583.90 crore, up 9.82% Y-o-Y

      Dr Lal PathLab Standalone September 2024 Net Sales at Rs 583.90 crore, up 9.82% Y-o-Y

    • Trade Spotlight: How should you trade Bharti Hexacom, HCL Technologies, Granules India, Dr Lal PathLabs, BSE, and others on Thursday?

      Trade Spotlight: How should you trade Bharti Hexacom, HCL Technologies, Granules India, Dr Lal PathLabs, BSE, and others on Thursday?

      The downward pressure may persist in the market, given the strong control exerted by bears over Dalal Street. Below are some trading ideas for the near term.

    • Hold Dr Lal Pathlabs; target of Rs 3100: ICICI Securities

      Hold Dr Lal Pathlabs; target of Rs 3100: ICICI Securities

      ICICI Securities recommended hold rating on Dr Lal Pathlabs with a target price of Rs 3100 in its research report dated October 24, 2024.

    • Dr Lal PathLab Consolidated September 2024 Net Sales at Rs 660.20 crore, up 9.8% Y-o-Y

      Dr Lal PathLab Consolidated September 2024 Net Sales at Rs 660.20 crore, up 9.8% Y-o-Y

    • Dr Lal PathLab Standalone September 2024 Net Sales at Rs 583.90 crore, up 9.82% Y-o-Y

      Dr Lal PathLab Standalone September 2024 Net Sales at Rs 583.90 crore, up 9.82% Y-o-Y

    • Stock Radar: HUL, Escorts Kubota, NLC India, Nuvoco Vistas, AU SFB, VIP Industries, Thyrocare, Dr Lal PathLabs in focus on Thursday

      Stock Radar: HUL, Escorts Kubota, NLC India, Nuvoco Vistas, AU SFB, VIP Industries, Thyrocare, Dr Lal PathLabs in focus on Thursday

      Stocks like Sona BLW Precision Forgings, Birlasoft, Birla Corporation, Fedbank Financial Services, Karnataka Bank, MAS Financial Services, Navin Fluorine International, Schaeffler India, and Piramal Pharma will also be in focus on October 24.

    • Trade Spotlight: How should you trade ICICI Bank, Phoenix Mills, Tube Investments of India, Unichem Labs and others on Wednesday?

      Trade Spotlight: How should you trade ICICI Bank, Phoenix Mills, Tube Investments of India, Unichem Labs and others on Wednesday?

      The Nifty 50 may see a minor rebound after the significant fall, but overall, the trend remains weak. Below are some trading ideas for the near term.

    • Trade Spotlight: How should you trade Dr Lal PathLabs, JK Paper, Jubilant Ingrevia, Anant Raj and others on Monday?

      Trade Spotlight: How should you trade Dr Lal PathLabs, JK Paper, Jubilant Ingrevia, Anant Raj and others on Monday?

      Overall sentiment remains weak, but given the somewhat oversold conditions, a bounce back cannot be ruled out early next week. Below are some trading ideas for the near term.

    • Dr Lal PathLab Consolidated June 2024 Net Sales at Rs 601.90 crore, up 11.26% Y-o-Y

      Dr Lal PathLab Consolidated June 2024 Net Sales at Rs 601.90 crore, up 11.26% Y-o-Y

    • Hold Dr Lal Pathlabs; target of Rs 3,240: ICICI Securities

      Hold Dr Lal Pathlabs; target of Rs 3,240: ICICI Securities

      ICICI Securities recommended hold rating on Dr Lal Pathlabs with a target price of Rs 3,240 in its research report dated August 08, 2024.

    • Dr Lal PathLab Standalone June 2024 Net Sales at Rs 534.50 crore, up 11.33% Y-o-Y

      Dr Lal PathLab Standalone June 2024 Net Sales at Rs 534.50 crore, up 11.33% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347